10/019337 531 DOCKET NO. JAB-1512

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Masure, et al.

Serial No. :

Art Unit:

Filed

: December 20, 2001

Examiner:

For

: NEUROTROPHIC FACTOR RECEPTOR

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Washington, D.C. 20231 on

December 20, 2001
(Date of Deposit)

Myra H. McCormack
(Name of applicant, assignee, or Registered Representative)

December 20, 2001

(Date of Signature)

Commissioner for Patents Washington, D.C. 20231

## INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under \$1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in \$1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under \$1.114, no additional fee is required.

$\square$ In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with [ ] the
first or second After Final Submission, therefore:
Statement in Accordance with §1.97(e) (attached);
or
☐ Please charge Deposit Account No. 10-0750/ /
the fee of $$180.00$ as set forth in $$1.17(p)$ .
$\square$ In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in §1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or an
action that otherwise closes prosecution and that it is
accompanied by one of:

10/019337

Statement in Accordance with \$1.97(e) (attached); or 19 DEC 2001
☐ Please charge Deposit Account No. 10-0750/ /
the fee of $$180.00$ as set forth in $$1.17(p)$ .
In accordance with §1.97(d), this Information
Disclosure Statement is being filed after the mailing date of
either a Final Action under §1.113 or a Notice of Allowance
under §1.311 but before the payment of the Issue Fee.
Applicant(s) hereby petition(s) for consideration of this
Information Disclosure Statement. Included are: Statement in
Accordance with §1.97(e) as set forth below and the fee of
\$180.00 as set forth in <b>§</b> 1.17(p).
Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
Copies of references listed on the attached Form PTO- 1449 are enclosed herewith EXCEPT THAT:
In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
There are no listed references which are not in the English language.

10/019337

П,	The relevance of thos	se listed	references whi	ich are	not
in the En	glish language is as f				
$\boxtimes$	Attached are copies of	of search	report(s) from	m	
	ding patent application Submission Under MPEP		.ch ale lisea		
	Attached are the fol- plications which may b the attached Submissi	oe deemed	relevant, which		
Deposit A	se charge any deficience count No. 10-0750/JAN				to
Supmireced		Respectf	ully submitted	,	
		Reg. No.	H LLLUM McCormack 36602 for Applicant		
Johnson & One Johns	Johnson son & Johnson Plaza swick, NJ 08933-7003				

(732) 524-6932 DATED: December 20, 2001



Approved for use through 10/31/2002. U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

> (use as many sheets as necessary) Sheet of

Under the Paperwork Reduction Act of 1995, no persons are required to respond t	o a collection of information unless it displayed	valid QMB epitteshnumber.
form 1449A/PTO	Application Number 🗘 U	
	Filing Date	December 19, 2001
DRMATION DISCLOSURE	First Named Inventor	Masur et al
·	Group Art Unit	
TEMENT BY APPLICANT	Examiner Name	
(use as many sheets as necessary)	Attorney Docket Number	JAB-1512

**U.S. PATENT DOCUMENTS U.S. Patent Document Date of Publication** Pages, Columns, Lines, Name of Patentee or Applicant Kind Code<sup>2</sup> where relevant passages Cite of Cited Document Examiner of Cited Document or relevant figures appear Initials (if known) Number mm-dd-yyyy No.1

## **FOREIGN PATENT DOCUMENTS** Date of Publication Pages, Columns, Lines, Foreign Patent Document of Cited Document where relevant Name of Patentee or passages or relevant mm-dd-yyyy T6 Cite Examiner Applicant of Cited Document figures appear Initials Number⁴ KindCode<sup>5</sup> Office<sup>3</sup> No.1 11/01/2001 wo 01/02557 **A**1 Janssen Pharmaceutica, NV Washington University 25/03/1999 wo 99/14235 A1 Millenium Pharmaceuticals, Inc. 03/02/2000 wo 00/05373 **A2** 07/10/1999 wo 99/50298 Α1 Millennium Pharmaceuticals, Inc. 18/09/1997 WO 97/33912 **A2** Genentech, Inc.

١	Examiner	Date	
	Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. s Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. e Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark. Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet

a collection of information unless it displays a	MENO CINICACULARITY INTRODUCE
Application Number	01019331
Filing Date	December 19, 2001
First Named Inventor	Masure et al
Group Art Unit	
Examiner Name	
Attorney Docket Number	JAB-1512

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
mudis	740.	JANE THOMPSON, EPAMINONDAS DOXAKIS, LUZIA G.P. PINON, PHILIP STRACHAN, ANNA BUJ- BELLO, SEAN WYATT, VLADIMIR L. BUCHMAN, AND ALUN M. DAVIES, "GFRQ-4, a New GDNF Family	
		Receptor", Mol. Cell. Neudrosci. 11, 117-126.	
		YASUSHI ENOKIDO, FRED DE SAUVAGE, JO-ANNE HONG, NATALIA NINKINA, ARNON ROSENTHAL, VLADIMIR L. BUCHMAN AND ALUN M. DAVIES, "GRFα-4 and the tyrosine kinase Ret form a functional receptor complex for persephin", Current Biology 8, 1019-1022	
		MART SAARMA, HANNU SARIOLA, "Other Neurotrophic Factors: Glial Cell Line-Derived Neurotrophic Factor (GDNF)", Microscopy Research and Technique, 45:292-302 1999	
		TERESA M. GUNN, KIMBERLY A. MILLER, LIN HE, RICHARD W. HYMAN, RONALD W. DAVIS, AREZOU AZARANI, STUART F. SCHLOSSMAN, JONATHAN S. DUKE-COHAN, GREGORY S. BARSH, "The mouse mahongany locus encodes a tansmembrane form of human attractin", Nature Vol. 398, 152-156, 1999	Ī
		MARIA DE FATIMA BONALDO, GREGORY LENNON, AND MARCELO BENTO SOARES, "Normalization and Subtraction: Two Approaches to Facilitate Gene Discovery", Genome Research, 6:791-806, 1996	
		MARIA LINDAHL, TONIS TIMMUSK, JARI ROSSI, MART SAARMA, MATTI S.AIRAKSINEN, "Expression and Alternative Splicing of Mouse Gfra4 Suggest Roles in Endocrine Cell Development", Molecular and Cellular Neuroscience 15, 522-533 2000	
		STEFAN MASURE, MIROSLAV CIK, EVERT HOEFNAGEL, CHRISTOPHER A. NOSRAT, ILSE VAN DER LINDEN, RIZALDY SCOTT, PAUL VAN GOMPEL, ANNE S. J. LESAGE, PETER VERHASSELT, CARLOS F. IBANEZ, ROBERT D.GORDON, "Mammalian GFRa-4, a divergent member of the GFRa family of coresceptors for GDNF family ligands, is a receptor for the neurotrophic factor persephin", American Society	
		for Biochemistry and Molecular Biology, Inc., 1-36, 2000.	
	ļ	MATTI S. AIRAKSINEN, ALEXEY TITIEVSKKY, MART SAARMA, "GDNF Family Neurotrophic Factor Signaling: Four Masters, One Servant?, Molecular and Cellular Neuroscience 13, 313-325 1999	
		EMBL DataBase Entry ID No. MMU276872 5/1/2000	
		EMBL DataBase Entry ID No. AF253318 10/26/2000	
		EMBL DataBase Entry ID No. AW528607 3/8/2000	
		EMBL DataBase Entry ID No. AU035938 10/8/1998	
		EMBL DataBase Entry ID No. AA823200 2/18/1998	
		EMBL DataBase Entry ID No. AF155960 7/28/1999	
	ļ		
	ļ		-
	<b></b>		<del> </del>

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231:

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.